Jan Skvarka's Insider Trades & SAST Disclosures
Jan Skvarka's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 60,000 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on Jan. 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jan Skvarka.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals Inc | Jan Skvarka | Director | Purchase of securities on an exchange or from another person at price $ 1.72 per share. | 31 Jan 2025 | 60,000 | 149,551 | - | 1.7 | 103,446 | Common Stock |
| Zentalis Pharmaceuticals Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,581 | 89,551 | - | 0 | Common Stock | |
| Monte Rosa Therapeutics Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 22,100 | 22,100 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 16,364 | 52,970 | - | 0 | Common Stock | |
| Monte Rosa Therapeutics Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,500 | 20,500 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2022 | 36,606 | 36,606 | - | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges